FIG 2.
Anti-HIV-1BaL activity of the CCL5-derived peptide R4.0 in combination with different HIV-1 entry and fusion inhibitors. (A to F) R4.0-induced HIV-1 inhibition tested by Env-mediated cell fusion inhibition assays in combination with CV-N (A), 2G12 (B), T20 (C), 2F5 (D), 4E10 (E), and MVC (F). (G) HIV-1 inhibition induced by the CCL5-derived peptide R3.0 (10) tested in combination with MVC by cell fusion inhibition assays using purified human CD4+ T cells. (H to I) R4.0-induced HIV-1 inhibition tested by cell fusion inhibition assays using purified human CD4+ T cells in combination with T20 (H) or MVC (I). The resulting dose-response curves of mixed inhibitors are referred to as R4.0 or R3.0 and indicated as “mix” (P values < 0.0001). Values are the means ± SD of results from two independent experiments performed in triplicate.